Lv6
1648 积分 2022-08-03 加入
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
8天前
已完结
Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies
8天前
已完结
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan
9天前
已完结
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
9天前
已完结
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer
14天前
已完结
Targeting KRAS in cancer
1个月前
已完结
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
2个月前
已完结
iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy
2个月前
已完结
Cancer therapy with iRGD as a tumor-penetrating peptide
2个月前
已完结
皖公网安备34019202002308
